Cargando…

Role of STK11 in ALK-positive non-small cell lung cancer

Anaplastic lymphoma kinase (ALK) inhibitors have been shown to be effective in treating patients with ALK-positive non-small cell lung cancer (NSCLC), and crizotinib, ceritinib and alectinib have been approved as clinical first-line therapeutic agents. The availability of these inhibitors has also l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Wen, Yan, Lu-Da, Yu, Zhi-Qiong, Li, Na, Yang, Yong-Hua, Wang, Meng, Chen, Yuan-Yuan, Mao, Meng-Xia, Peng, Xiao-Chun, Cai, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9073580/ https://www.ncbi.nlm.nih.gov/pubmed/35527776 http://dx.doi.org/10.3892/ol.2022.13301

Ejemplares similares

STK3-ALK, a Novel ALK Rearrangement in Non-Small Cell Lung Cancer With Sensitivity to Tyrosine Kinase Inhibitors: A Case Report
por: Feng, Chunlai, et al.
Publicado: (2021)

Molecular Signatures of KRAS-Mutated Lung Adenocarcinoma: Analysis of Concomitant EGFR, ALK, STK11, and PD-L1 Status
por: Hsu, Jim, et al.
Publicado: (2022)

The Importance of STK11/LKB1 Assessment in Non-Small Cell Lung Carcinomas
por: Mograbi, Baharia, et al.
Publicado: (2021)

Unraveling the Role of STK11/LKB1 in Non-small Cell Lung Cancer
por: Sumbly, Vikram, et al.
Publicado: (2022)

Functional assessment of somatic STK11 variants identified in primary human non-small cell lung cancers
por: Donnelly, Liam L, et al.
Publicado: (2021)

Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer
por: Pécuchet, Nicolas, et al.
Publicado: (2015)

The efficacy and safety of ALK inhibitors in the treatment of ALK‐positive non‐small cell lung cancer: A network meta‐analysis
por: Fan, Junsheng, et al.
Publicado: (2018)

Cardiac glycosides display selective efficacy for STK11 mutant lung cancer
por: Kim, Nayoung, et al.
Publicado: (2016)

Construction of an STK11 Mutation and Immune-Related Prognostic Prediction Model in Lung Adenocarcinoma
por: Tang, Bo, et al.
Publicado: (2023)

TERT Mutations in Non–Small Cell Lung Cancer: Clinicopathologic Features and Prognostic Implications
por: Yang, Liu, et al.
Publicado: (2023)

Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
por: Barrows, Stephanie M, et al.
Publicado: (2019)

Somatic mutations of STK11 gene in human papillomavirus positive and negative penile cancer
por: Annunziata, Clorinda, et al.
Publicado: (2013)

Case report: Concomitant EGFR mutation and ALK rearrangement in non-small cell lung cancer
por: Hu, Haoyue, et al.
Publicado: (2023)

Outcomes of patients with stage III non-small cell lung cancer (NSCLC) that harbor a STK11 mutation
por: An, Josiah, et al.
Publicado: (2021)

Clinical outcomes and immune phenotypes associated with STK11 co-occurring mutations in non-small cell lung cancer
por: Malhotra, Jyoti, et al.
Publicado: (2022)

Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations
por: Lou, Na-Na, et al.
Publicado: (2016)

ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer
por: Pilling, Amanda B., et al.
Publicado: (2018)

Peutz-Jeghers syndrome with germline mutation of STK11
por: Chae, Hyun-Dong, et al.
Publicado: (2014)

Prognostic role of multiple abnormal genes in non-small-cell lung cancer
por: Yan, Lu-Da, et al.
Publicado: (2022)

Relevance of STK11 Mutations Regarding Immune Cell Infiltration, Drug Sensitivity, and Cellular Processes in Lung Adenocarcinoma
por: Li, Zhenqing, et al.
Publicado: (2020)

ALK Inhibitors in the Treatment of ALK Positive NSCLC
por: Khan, Muhammad, et al.
Publicado: (2019)

Overexpression and Selective Anticancer Efficacy of ENO3 in STK11 Mutant Lung Cancers
por: Park, Choa, et al.
Publicado: (2019)

Atezolizumab prolongs overall survival over docetaxel in advanced non-small-cell lung cancer patients harboring STK11 or KEAP1 mutation
por: Nie, Wei, et al.
Publicado: (2021)

The Molecular Detection and Clinical Significance of ALK Rearrangement in Selected Advanced Non-Small Cell Lung Cancer: ALK Expression Provides Insights into ALK Targeted Therapy
por: Zhang, Ning-Ning, et al.
Publicado: (2014)

Complete STK11 Deletion and Atypical Symptoms in Peutz-Jeghers Syndrome
por: Jang, Myeong Sun, et al.
Publicado: (2017)

Ceritinib for ALK-Rearrangement–Positive Non–Small Cell Lung Cancer
por: Nix, Nancy M., et al.
Publicado: (2015)

Immunotherapy Mechanism of Esophageal Squamous Cell Carcinoma with the Effect of STK11/AMPK Signaling Pathway
por: Xia, Yang, et al.
Publicado: (2022)

Mutations in STK11 gene in Czech Peutz-Jeghers patients
por: Vasovčák, Peter, et al.
Publicado: (2009)

Mutational Analysis of STK11 h Gene in Ovarian Carcinomas
por: Nishioka, Yoshihiro, et al.
Publicado: (1999)

Characterization of the STK11 splicing variant as a normal splicing isomer in a patient with Peutz–Jeghers syndrome harboring genomic deletion of the STK11 gene
por: Masuda, Kenta, et al.
Publicado: (2016)

STK39, overexpressed in osteosarcoma, regulates osteosarcoma cell invasion and proliferation
por: Huang, Tao, et al.
Publicado: (2017)

A Critical Review of the Prognostic and Predictive Implications of KRAS and STK11 Mutations and Co-Mutations in Metastatic Non-Small Lung Cancer
por: Manolakos, Peter, et al.
Publicado: (2023)

Concurrent Mutations in STK11 and KEAP1 Cause Treatment Resistance in KRAS Wild-type Non-small-cell Lung Cancer
por: Sumii, Masahiko, et al.
Publicado: (2023)

Combined effect of ALK and MEK inhibitors in EML4–ALK-positive non-small-cell lung cancer cells
por: Tanizaki, J, et al.
Publicado: (2012)

Mechanisms of suppression of cell growth by dual inhibition of ALK and MEK in ALK-positive non-small cell lung cancer
por: Shrestha, N., et al.
Publicado: (2019)

STK11 rs2075604 Polymorphism Is Associated with Metformin Efficacy in Chinese Type 2 Diabetes Mellitus
por: Li, Qingchu, et al.
Publicado: (2017)

How I treat ALK-positive non-small cell lung cancer
por: McCusker, Michael G, et al.
Publicado: (2019)

STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort
por: Papillon-Cavanagh, Simon, et al.
Publicado: (2020)

STK11/LKB1 Modulation of the Immune Response in Lung Cancer: From Biology to Therapeutic Impact
por: Pons-Tostivint, Elvire, et al.
Publicado: (2021)

STK11 mutation impacts CD1E expression to regulate the differentiation of macrophages in lung adenocarcinoma
por: Zhang, Qingfeng, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pglbnq8p1se1hkbmn8ce5piilh